

**Balixafortide (a CXCR4 antagonist) + eribulin in HER2-n
(MBC): Survival outcomes of the phase I trial.**

Journal of Clinical Oncology

37, 2606-2606

DOI: [10.1200/jco.2019.37.15_suppl.2606](https://doi.org/10.1200/jco.2019.37.15_suppl.2606)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Immunotherapies targeting stimulatory pathways and beyond. Journal of Hematology and Oncology, 2021, 14, 78.	6.9	23
2	Update of early phase clinical trials in cancer immunotherapy. BMB Reports, 2021, 54, 70-88.	1.1	27